Antimicrobial de-escalation of treatment for healthcare-associated pneumonia within the Veterans Healthcare Administration

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 539-546

  Madaras Kelly, Karl ^a,b   Jones, Makoto ^c,d   Remington, Richard ^a,e   Caplinger, Christina M ^a,b   Huttner, Benedikt ^f   Jones, Barbara ^c,g   Samore, Matthew ^c,d  

^a Boise VA Medical Center   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Quantified Inc   (United States)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOPENICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFDINIR; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; DOXYCYCLINE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM CULTURE; COHORT ANALYSIS; DRUG DOSE ESCALATION; FEMALE; HEALTH CARE ASSOCIATED PNEUMONIA; HEALTH CARE FACILITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; RETROSPECTIVE STUDY; CROSS INFECTION; PNEUMONIA, BACTERIAL; PROCEDURES; PUBLIC HOSPITAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG THERAPY; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES;

EID: 84959918887     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv338     Document Type: Article

References (40)

1. Promoting Antimicrobial Stewardship in Human Medicine. http://www.idsociety.org/Stewardship_Policy/.
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
3. Dellinger RP, Levy MM, Rhodes A et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
4. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
5. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33: 322-77.
6. CDC. Evidence to Support Stewardship. http://www.cdc.gov/getsmart/healthcare/evidence.html.
7. Masterton RG. Antibiotic de-escalation. Crit Care Clin 2011; 27: 149-62.
8. Braykov NP, Morgan DJ, Schweizer ML et al. Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. Lancet Infect Dis 2014; 14: 1220-77.
9. Alvarez-Lerma F, Alvarez B, Luque P et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10: R78.
10. Kollef MH, Morrow LE, Niederman MS et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129: 1210-8.
11. Leone M, Bechis C, Baumstarck K et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40: 1399-408.
12. Ahmad F, Pogue JM, Marchaim D et al. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system. J Infect Public Health 2014; 7: 50-3.
13. Madaras-Kelly KJ, Jones M, Remington R et al. Development of an antibiotic spectrum score based on Veterans Affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach. Infect Control Hosp Epidemiol 2014; 35: 1103-13.
14. Madaras-Kelly KJ, Jones M, Remington R et al. Description and validation of a spectrum score method to measure antimicrobial de-escalation from electronic medical records data. BMC Infect Dis 2015; 15: 197.
15. Aronsky D, Haug PJ, Lagor C et al. Accuracy of administrative data for identifying patients with pneumonia. Am J Med Qual 2005; 20: 319-28.
16. Madaras-Kelly KJ, Remington RE, Sloan KL et al. Guideline-based antibiotics and mortality in healthcare-associated pneumonia. J Gen Intern Med 2012; 27: 845-52.
17. Korom-Djakovic D, Canamucio A, Lempa M et al. Organization complexity and primary care providers' perceptions of quality improvement culture within the Veterans Health Administration. Am J Med Qual 2014; doi:10.1177/1062860614559743.
18. Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia a distinct entity needing specific therapy? Curr Opin Infect Dis 2012; 25: 166-75.
19. Chalmers JD, Rother C, Salih W. et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58: 330-9.
20. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
21. Schlueter M, James C, Dominguez A et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 2010; 38: 357-62.
22. Labelle AJ, Arnold H, Reichley RM et al. A comparison of culturepositive and culture-negative health-care-associated pneumonia. Chest 2010; 137: 1130-7.
23. Johannsson B, Beekmann SE, Srinivasan A et al. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol 2011; 32: 367-74.
24. VHA Directive 1031. Antimicrobial Stewardship Programs. http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2964.
25. Executive Order-Combating Antibiotic-Resistant Bacteria. http://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combatingantibiotic-resistant-bacteria.
26. Koupetori M, Retsas T, Antonakos N et al. Bloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcome. BMC Infect Dis 2014; 14: 272.
27. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40: 32-40.
28. Shime N, Kosaka T, Fujita N. De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli. Infection 2013; 41: 203-10.
29. Boyce JM, Pop OF, Abreu-Lanfranco O et al. A trial of discontinuation of empiric vancomycin therapy in patients with suspectedmethicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother 2013; 57: 1163-8.
30. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection 2011; 39: 319-25.
31. Morel J, Casoetto J, Jospé R et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care 2010; 14: R225.
32. De Waele JJ, Ravyts M, Depuydt P et al. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care 2010; 25: 641-6.
33. Eachempati SR, Hydo LJ, Shou J et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66: 1343-8.
34. Schouten JA, Hulscher ME, Trap-liefers J et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. Clin Infect Dis 2007; 44: 931-41.
35. Kim JW, Chung J, Choi SH et al. Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Crit Care 2012; 16: R28.
36. Joung MK, Lee JA, Moon SY et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 2011; 15: R79.
37. Singh N, Rogers P, Atwood CW et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 505-11.
38. Rosen AK, Loveland S, Anderson JJ et al. Evaluating diagnosis-based case-mix measures: how well do they apply to the VA population? Med Care 2001; 39: 692-704.
39. Linden A. Assessing regression to the mean effects in health care initiatives. BMC Med Res Methodol 2013; 13: 119.
40. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34: 215-20.